Company Filing History:
Years Active: 2013-2017
Title: Innovator Spotlight: Chitra Telang
Introduction
Chitra Telang, a dedicated inventor based in Brookfield, CT, has made significant strides in the pharmaceutical field with her innovative contributions. With a focus on developing effective treatments for Hepatitis C, Chitra holds two patents that showcase her expertise and commitment to advancing healthcare solutions.
Latest Patents
Chitra's latest patents include pivotal research in the formulation of solid oral dosage forms for Hepatitis C virus (HCV) inhibitors. The first patent details a solid oral dosage formulation of an HCV inhibitor in the amorphous state. This innovation involves a specific compound (referred to as Compound (1)) that can be used to combat HCV infection. The formulation includes various pharmaceutically acceptable excipients, making it a robust solution for patients.
Her second patent involves the discovery of novel sodium salt forms of the same Compound (1) and outlines methods for preparing these forms, as well as pharmaceutical compositions for treating HCV. These discoveries highlight innovative approaches to therapeutic design aimed at enhancing patient outcomes in the struggle against Hepatitis C.
Career Highlights
Chitra is currently affiliated with Boehringer Ingelheim International GmbH, a global leader in the pharmaceutical industry. Her work there emphasizes her role in pharmacological innovation, particularly in targeting HCV. Her career reflects a commitment to research and development in a field that directly impacts public health.
Collaborations
Throughout her career, Chitra has collaborated with notable professionals in her field, including her coworkers Zeren Wang and Li Zhong. These collaborations have been crucial in the progression of her research, facilitating the pooling of ideas and resources that drive successful innovation in healthcare.
Conclusion
Chitra Telang exemplifies the spirit of innovation within the pharmaceutical industry. With her patents and collaborative efforts, she continues to make valuable contributions toward advancing treatments for Hepatitis C. As she continues her work at Boehringer Ingelheim International GmbH, her future inventions will undoubtedly play an essential role in improving health outcomes for patients affected by this viral infection.